Princeton, New Jersey--(Newsfile Corp. - March 1, 2023) - Xybion Digital Inc. (TSXV: XYBN) ("Xybion" or the "Company"), a global, low-code SaaS company that enables digital transformation in highly regulated industries like Life Sciences, announced that it will be attending the Roth Conference on March 12-14, 2023. The conference is one of the world's premier investor conferences and brings together leaders from around the world from a variety of growth sectors. Xybion Digital has been invited to attend.
Dr. Pradip Banerjee, Chairman and CEO of Xybion Digital, said, "We are excited to be attending the Roth Conference this year. It is an incredible opportunity to showcase our unified software solutions to digitally transform the life sciences R&D and laboratory processes with embedded quality and compliance software to help our clients bring new critical medicines to market faster and save more lives." He added, "We look forward to connecting with investors, analysts and industry leaders, sharing our vision, strategy and investment thesis for the digital transformation of life sciences and healthcare companies."
| Conference Details: | |
| Event: | The 35th Annual Roth Conference |
| Format: | 1-on-1, Group Meetings, Presentations, and Panel Discussions |
| Date: | Sunday, March 12, 2023 - Tuesday, March 14, 2023 |
| Venue: | Ritz Carlton, Laguna Niguel. Dana Point, California. |
| Registration: | www.b2idigital.com/ |
About Xybion Digital Inc.
Xybion is a global SaaS company that helps enterprise life sciences organizations accelerate new drug development into approved medicines that may save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that is cost-effective, ready to deploy, and easy to use. Xybion has over 160 clients in 29 countries using its low-code software to accelerate timelines, improve compliance, expand capacity, minimize operating risks, and reduce expenses while keeping employees safe.
Learn more about Xybion at https://www.xybion.com/
For further information: For more information regarding Xybion Digital Inc., please contact Pradip Banerjee, Chief Executive Officer, PBanerjee@xybion.com, 609-512-5790 x122
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements ("forward-looking statements") in this news release may contain forward-looking information concerning relating to the release of financial results, plans related to the Company's business and other matters that may occur in the future, made as of the date of this news release. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including with respect to the timing of such release. Although management considers these assumptions to be reasonable based on information available to it, they may prove to be incorrect.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. Such factors include, among others, the risks described in disclosure documents filed by the Company on SEDAR. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/156846
